elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Pricing
Log in
Sign up
Home
/
Subjects
/
Nivolumab
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Nivolumab
RIS
0.001
(Research Intensity Score)
Papers
106
Top papers
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
2022 · 2627 citations
Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
2023 · 479 citations
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
2019 · 3728 citations
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
2021 · 1211 citations
NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.
2025 · 58 citations
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
2023 · 140 citations
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
2018 · 4676 citations
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial
2025 · 40 citations
Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial
2025 · 28 citations
Newest papers
Abstract PD7-10: Neo-n (neon): three-year event-free survival and ultrasensitive ctdna dynamics in early triple-negative breast cancer (tnbc) treated with neoadjuvant carboplatin/paclitaxel and nivolumab
2026 · 3 citations
Papillary renal cell carcinoma – exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review
2026 · 1 citations
Primed to React: Neutrophil‐To‐Lymphocyte Ratio to Predict Severe Checkpoint Inhibitor Pneumonitis
2026
Treatment of Early-Stage Lung Cancer
2026
Lung cancer across borders: From molecular epidemiology to precision treatment strategies
2026
Real-World Patterns of First-Line Treatment Selection After the Introduction of Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Carcinoma
2026
Autoimmune GFAP astrocytopathy associated with sintilimab immunotherapy in a patient with esophageal squamous cell carcinoma: a case report and literature review
2026
First-Line Nivolumab Plus Ipilimumab in Inoperable Epithelioid Malignant Pleural Mesothelioma: Real-World Experience From an Indian Tertiary Care Center
2026
Copanlisib in combination with nivolumab formicrosatellite stable colorectal cancer: a phase 1/2 trial
2026
Browse all papers →
Nivolumab's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Nivolumab's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link